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treatment time and simple radioprotection measures should position 
this new medical device as an interesting alternative for breast IORT.  
 
  
   
OC-0480   
External radiation therapy, extended surgery and intraoperative 
electrons for oligorrecurent pelvic cancer  
F.A. Calvo1, C.V. Sole1, P. Alvarez de Sierra2, J. Blanco1, M. Gomez-
Espi1, M. Lozano1, R. Herranz1, L. Gonzalez-Bayon2, C. Gonzalez1, J.L. 
Garcia Sabrido1 
1Hospital Gregorio Marañón, Radiation Oncology, Madrid, Spain  
2Hospital Gregorio Marañón, General Surgery III, Madrid, Spain  
 
Purpose/Objective: To analyze prognostic factors associated with 
survival in patients after intensified radio-surgical rescue of 
oligorecurrent pelvic cancer, particularly the influence of external 
beam radiation therapy (EBRT).  
Materials and Methods: From January 1995 to december 2011, 81 
patients [colorectal (46%); gynecologic (26%); retroperitoneal sarcoma 
(18%)] underwent extended surgery [multiorgan (58%), bone (23%), 
vascular (9%), soft tissue (43%)] and intraoperative electron-beam 
radiation therapy [IOERT (10-15 Gy)] to the pelvic recurrence tumor 
bed. 35 (43%) of these patients also received EBRT (30.6-50.4 Gy). 
Survival outcomes were estimated using the Kaplan-Meier method, 
and risk factors were identified by univariate and multivariate 
analyses.  
Results: Median follow-up was 34 months (3-189 months), and the 1- 
3-, and 5-year rates of locoregional control (LRC) were 83%, 53%, and 
41%, respectively. Univariate Cox proportional hazard analysis 
revealed worse LRC for those patients who did not received integrated 
EBRT treatment for the pelvic recurrence rescue (p=0.003), and had 
non-radical resection (p=0.01). On multivariate analysis, integrated 
EBRT treatment, non-radical resection, and tumor fragmentation 
retained significance (p=0.002,p=0.004, and p=0.05, respectively).  
Conclusions: EBRT treatment integrated for rescue, radical resection, 
and abscence of tumor fragmentation are associated with improved 
LRC in patients with oligorecurrent pelvic cancer. Present results 
suggest that patients with oligorecurrent pelvic disease ma ybenefit 
from EBRT treatment integrated with extended surgery and IOERT. 
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Purpose/Objective: To analyze prognostic factors associated with 
survival in patients after intraoperative electrons containing resective 
surgical rescue of locally recurrent rectal cancer (LRRC), particularly 
the influence of an integrated component of external beam radiation 
therapy (EBRT).  
Materials and Methods: From January 1995 to december 2011, 60 
patients with pelvic recurrence from rectal inicial cancer primaries 
underwent extended surgery [n=38; multiorgan(43%), bone (28%), soft 
tissue (38%)] or non-extended (n=22) surgical resection, including a 
component of intraoperative electron-beam radiation therapy (IOERT) 
to the pelvic recurrence tumor bed. Twenty-eight (47%) of these 
patients were amenable and also received EBRT (range, 30.6-50.4 Gy). 
Survival outcomes were estimated using the Kaplan-Meier method, 
and risk factors were identified by univariate and multivariate 
analyses.  
Results: Median follow-up was 36 months (range, 2-189), the 1- 3-, 
and 5-year rates of LRC were 86%, 52%, and 44%, respectively. On 
univariate analysis, patients with R1 resection (5-year LRC=55.7% vs. 
19.0%, p=0.02) and not receiving EBRT (5-year LRC= 56.2% vs. 32.0%, 
p=0.02) were at a significantly higher risk of LR recurrence. Patients 
without tumor fragmentation, non-metastasic lymph nodes, abscence 
of perineural invasion and age > 55 had a lower risk of LRrelapse. We 
observed on multivariate analysis that margin status (R1resection), 
EBRT at the time of pelvic recurrence, no tumor fragmentation and 
non-lymph node metastasis retained significance with regard to LR 
relapse.  
Conclusions: EBRT treatment integrated for rescue, resection 
radicality, and not involved fragmented resection specimens are 
associated with improved LRC in patients with locally recurrent rectal 
cancer. Additionaly tumor fragmentation could be compensated by 
EBRT. Present results suggest that a significant group of patients with 
oligorecurrent pelvic disease may benefit from EBRT treatment 
integrated with extended surgery and IOERT. 
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Purpose/Objective: Patients with locally advanced rectal cancer are 
reported to have a dismal prognosis, challenging expert 
interdisciplinary manaegment. The purpose of this study is to analyze 
the 15-years results of neoadjuvant-based multimodality treatment 
for locally advanced rectal cancer (LARC) with particular emphasis on 
intraoperative electron-beam radiotherapy (IEORT). 
Materials and Methods: A total of 335 patients with LARC [≥cT3 93% 
and/or cN+ 69%) who underwent multimodality treatment between 
1995 and 2011 were studied. The basic treatment principle was 
preoperative(chemo)radiotherapy, intended radical surgery, IOERT 
and elective adjuvant chemotherapy (aCT). In uni- and multivariate 
analyses, risk factors for all loco-regional recurrence (LR), IOERT in-
field recurrence (IFR) and IOERT out-field recurrence (OFR) were 
studied. 
Results: Median follow-up for all patients was 52. 2 months (range, 1-
184), the 5 year overall survival, disease-free survival, local control, 
in-field and out-field control rates were 73.6%, 69.4%, 94.4%, 97.0% 
and 93.4%, respectively. Synchronic local and distant metastasic 
disease was present in 16% of the patients that recurred. In 
multivariate analysis distal margin distance < 20 mm [HR 3.74 (1.79-
7.82),p < 0.001], ypN+ [HR 2.53 (1.16-5.54), p = 0.02] and tumor 
histology grade 3[HR 7.0 (2.8-17.56), p < 0.001]; Non-sphincter 
preserving surgery [HR 6.49(1.58-26.32), p=0.009], cT4 [HR 6.24 (1.34-
29.1)], ypN+ [HR 7.41 (1.96-28.0)] and tumor histology grade 3 [HR 8.5 
(2.8.-27.44), p < 0.001]; gender [HR 2.87 (1.10-7.46), p = 0.03], distal 
margin distance < 20 mm [HR 4.37 (1.68-11.34), p = 0.002] and no aCT 
[HR 2.62(1-03-1.68), p = 0.04] were associated with increased risk of 
LR, IFR and OFR, respectively.  
Conclusions: Overall oncological results after multimodality 
treatment of LARC are promising. The positive impact of 
intraoperative radiotherapy on pelvic control does justify the inclusion 
of this therapeutic modality in prospective multi-institutional trials. 
Cancer death with uncontrolled pelvic progression was 28%. Adding 
aCT to the treatment may contribute to improve LR rates.  
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Purpose/Objective: A joint analysis of data from centres within the 
ISIORT-Europe program was performed to investigate the role of intra-
operative radiotherapy (IORT) and contribute to homogenize 
treatment modalities. 
Materials and Methods: All ISIORT-Europe centres were invited to 
record the data of their IORT treatments using the appropriate file 
available at the website  
www.isiort.org/htm/isiort_europe.htm and send them to the data 
centre. All information (institution, patient data, tumour data, 
treatment modality) were therefore collected in a common database 
to analyse clinical and technical aspects of the treatments. 
Results: Twenty one centers from Italy, Spain, Poland, Austria, 
Germany, France and Israel participated to this survey and data of 
3,769 IORT cases from 1992 to 2012 were collected. Table 1 shows, as 
an example, some technical aspects of the treatment data. 
 
Conclusions: The availability of data from several centres active in 
IORT treatments may allow to perform data analysis useful to 
disseminate knowledge about clinical and technical aspects of this 
radiation modality and to dispose a basis for further clinical 
multicenter trials. 
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Purpose/Objective: Within the last years two types of miniaturized x-
ray sources have become commercially available for radiation therapy 
treatment (RTT) and today about 300 devices are applied in clinics 
worldwide. The two types are manufactured by two different vendors: 
the 'Intrabeam®'-system from Carl Zeiss Meditec AG and the 'Axxent®' 
tube from Xoft (iCad, Inc.). Both devices emit an x-radiation field 
which energy distributionis given by a continuous Bremsstrahlung-
spectrum with a maximum energy of 50keV and characteristic 
fluorescence lines induced by the material of the electron target and 
the materials in the pathway of the emitted photons. Despite this 
similarity the dosimetric and quality assurance procedures are 
different. 
The German National Metrology Institute (PTB) is developing a primary 
standard in terms of absorbed dose to water for miniature x-ray 
sources which does not exist so far. In addition investigations will be 
done in order to find the best method for the dissemination of this 
quantity. As a basis of this work the spatial and energy distribution of 
the radiation fields must be studied. It was reported that the focal 
spot of the X-ray tube shifts with increasing beam current in case of 
the 'Axxent®' tube [1]. To answer the question if this effect arises a 
change of the spectrum spectrometry must be performed at different 
beam currents, also at the maximum beam current. Generally, spectra 
taken at high count rates show typical artefacts such as pulse pile-up 
distortions. In this work an algorithm is presented to consider these 
artefacts in the data evaluation. 
Materials and Methods: Spectra were measured with an HPGe-
Detecor (GLP 0110P, Canberra Industries) in combination with an 
analogue desktop spectrum analyzer (Eagle 5004) featuring pulse pile-
up rejector circuits for high count rate spectrometry. The algorithm to 
eliminatethe remaining pulse-pile up artifacts was developed in 
MATLAB and is based on the approach that by using pile-up rejector 
circuits the remaining artifacts are given by a single or multiple 
convolution of the primary spectrum with itself. 
Results: In Figure 1 three spectra of the 'Axxent®'tube taken at 50 kV 
tube voltages are presented. The spectrum measured at 300 µA beam 
current is given in a black dash-dotted line. The count rate during the 
measurement was more than 160000 Cts/s and the dead time of the 
spectrometry system was more than 65%. The spectrum shows 
significant pulse pile-up artefacts, clearly visible at photon energies 
above 50 keV. The spectrum reconstructed from the first one with the 
developed algorithm is given in full red line. For comparison, a 
spectrum measured at 10 µA beam current is shown in blue dashed 
line. 
 
  
Conclusions: The spectrum reconstructed by means of the developed 
algorithm matches the spectrum taken at 10 µA. These findings 
assume to support the following conclusions: first the proposed 
algorithm works properly and second the spectra of the tube don't 
alter with varying beam currents. 
[1] P. Sievers, et al. 41. DGMP Annual Meeting, Freiburg im Br. 29. 09. 
– 02.10.2010, Germany 
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Purpose/Objective: Intra-operative radiotherapy (IORT) is an 
investigational approach for the treatment of locally advanced 
prostate cancer. The aim of this study is to analyze clinical, technical 
and organizational parameters to optimize the IORT procedure at our 
Institution. 
Materials and Methods: In 2005, a program for IORT in high risk, 
locally advanced prostate cancer started at our Institution as 
anticipated boost for a dose of 12 Gy. The following clinical, technical 
and organizational parameters were defined for quality assurance 
(QA): 
- multidisciplinary discussion by a dedicated staff, 
- patients age < 76 years, probability of organ-confined disease < 25% 
according to MSKCC nomogram, KPS > 90, 
- pre-surgical staging with bone scan and pelvic CT and/or MRI,  
- specific informed consensus,  
- complications assessment, 
- measurement of prostate anterior-posterior (A-P) and transverse 
diameters on pre-surgical imaging and intra-operative ultrasound to 
define the electron beam energy, 
- 'in vivo' rectal dose detection by 4 radio-chromic films positioned on 
a rectal probe, 
- collimator diameter choose based on pre-operative imaging and on 
target identification directly in the surgical field, 
- target including prostate plus a circumferential margin (0.5 cm), 
- bevel angle (range 0°-30°) adapted on pubic arc anatomy and 
prostate exposure, 
- multidisciplinary meeting for timing and technical details,  
- evaluation of the procedure duration.  
Results: Until July 2012, 84 patients were selected for IORT and 100% 
of them accepted the procedure. Median age was 68 years (range 52-
76). Median iPSA was 14.6 ng/ml (range 2.0-63.9) and median GS was 
8 (range 4-10); 64/84 met the selection criteria regarding the organ-
confined disease. No major intra or post-operative complications 
occurred; 70% of patients required transfusion. We observed minor 
complications in 13/84 cases (15.5%) (lymphoceles, urethral-bladder 
anastomosis, strictures, pelvic haematomas). Median dose to the 
